Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
No results matched your search
Uniqure NV (QURE)
Add to/Remove from a Portfolio
Add to Portfolio
32.95
-1.80
-5.18%
After Hours
33.00
+0.05
+0.15%
0:34:03 - Real-time Data
- Volume: 678,325
- Bid/Ask: 32.60 / 35.97
- Day's Range: 32.72 - 35.50
Uniqure NV
32.95
-1.80
-5.18%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Options
- Index Component
Prev. Close34.75
Day's Range32.72 - 35.5
Revenue6.04M
Open34.54
52 wk Range32.78 - 71.45
EPS - 2.82
Volume678,325
Market Cap1.48B
Dividend (Yield)N/A (N/A)
Average Volume (3m)549,291
P/E RatioN/A
Beta1.37
1-Year Change - 38.56%
Shares Outstanding44,993,987
Next Earnings DateMay 03, 2021
What is your sentiment on Uniqure NV?
Members' Sentiments:
or
Market is currently closed. Voting is open during market hours.
Uniqure NV News
UniQure's stock rallies 7% on positive safety data for Huntington's disease treatment
By MarketWatch - Feb 08, 2021
Shares of UniQure gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical...
No Safety Concerns Observed In Uniqure's Early-Stage Huntington's Gene Therapy Study, DSMB Says
By Benzinga - Feb 08, 2021
Independent Data Safety Monitoring Board (DSMB) has reviewed the six-month safety data from the first two enrolled patients and 90-day safety data from the next two enrolled...
Technical Summary
| Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Filter Table By:
| Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
|---|---|---|---|---|---|
| Emerging Patterns | |||||
| Inverted Hammer | 30 | Current | |||
| Three Black Crows | 1D | Current | |||
| Completed Patterns | |||||
| Engulfing Bearish | 1D | 2 | Mar 02, 2021 | ||
| Engulfing Bearish | 1M | 3 | Dec 20 | ||
| Three Black Crows | 15 | 3 | Mar 04, 2021 21:00 | ||
Trending Stocks
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| MTN Nigeria | 162.00 | 162.00 | 162.00 | -8.00 | -4.71% | 599.06K | 04/03 | ||
| FBN Holdings | 7.05 | 7.10 | 6.75 | -0.05 | -0.70% | 31.25M | 04/03 | ||
| Guaranty Trust Bank | 31.50 | 31.80 | 31.05 | -0.20 | -0.63% | 15.50M | 04/03 | ||
| Zenith Bank | 25.30 | 25.65 | 25.30 | -0.25 | -0.98% | 38.65M | 04/03 | ||
| UBA | 7.95 | 8.15 | 7.75 | -0.30 | -3.64% | 26.78M | 04/03 | ||
| ETI | 5.00 | 5.00 | 5.00 | -0.20 | -3.85% | 2.15M | 04/03 | ||
| Forte Oil Plc | 14.65 | 14.65 | 14.65 | -1.60 | -9.85% | 1.07M | 04/03 | ||
| Nestle Nigeria | 1,350.00 | 1,350.00 | 1,350.00 | 0.00 | 0.00% | 71.83K | 04/03 | ||
| Nem | 1.730 | 1.720 | 1.720 | -0.190 | -9.95% | 471.84K | 04/03 | ||
| Wema Bank | 0.60 | 0.62 | 0.60 | -0.04 | -6.15% | 1.63M | 04/03 |
Uniqure NV Company Profile
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Read More
Write your thoughts about Uniqure NV
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.